MEST and osteosarcoma: Chr7q21.3-q32.3 loss comprises the alpha/beta hydrolase MEST (Mesoderm-specific transcript) which has the highest significant negative fold change (log2 Fold Change −9.94; adjusted p value 8.78×10-173) and has been implicated in osteosarcoma oncogenesis [12,13].